Skip to main content
HR 916 103th Congress House Health Advice and consent of the Senate Congressional reporting requirements Cost of living adjustments Department of Health and Human Services Drug industry Drugs Excess profits tax Executive reorganization Income tax Patents Prescription pricing Presidential appointments Price regulation Restrictive trade practices Tax preferences Taxation

Prescription Drug Prices Review Board Act of 1993

Introduced: February 16, 1993 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 103rd Congress ended
It never became law before the 103rd Congress (1993–1994) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 19 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 27, 1993
Sponsor introductory remarks on measure. (CR E1889)
Jul 14, 1993
Referred to the Subcommittee on Intellectual Property and Judicial Administration.
Jul 13, 1993
Sponsor introductory remarks on measure. (CR E1745-1746)
Jun 23, 1993
Sponsor introductory remarks on measure. (CR E1598)
Jun 17, 1993
Sponsor introductory remarks on measure. (CR E1539)
Jun 16, 1993
Sponsor introductory remarks on measure. (CR E1532-1533)
Jun 14, 1993
Sponsor introductory remarks on measure. (CR E1486)
Jun 8, 1993
Sponsor introductory remarks on measure. (CR E1419-1420)
May 25, 1993
Sponsor introductory remarks on measure. (CR E1346)
May 18, 1993
Sponsor introductory remarks on measure. (CR E1273)
May 13, 1993
Sponsor introductory remarks on measure. (CR H2486)
May 5, 1993
Sponsor introductory remarks on measure. (CR E1152-1153)
Mar 24, 1993
Sponsor introductory remarks on measure. (CR E760)
Mar 1, 1993
Referred to the Subcommittee on Health and the Environment.
Feb 17, 1993
Sponsor introductory remarks on measure. (CR H658-659)
Feb 16, 1993
Referred to the House Committee on Ways and Means.
Feb 16, 1993
Referred to the House Committee on Judiciary.
Feb 16, 1993
Referred to the House Committee on Energy and Commerce.
Feb 16, 1993
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Prescription Drug Prices Review Board Act of 1993 - Establishes in the Food and Drug Administration the Patented Medicine Prices Review Board which shall have the power to decrease the length of term of a prescription drug patent if, after notice and a hearing, it is found that the drug's price is excessive. Defines the term excessive price. Allows the Board to require the recapture of tax benefits provided to the patentee of an excessively priced drug.

What's happening now July 27, 1993

Sponsor introductory remarks on measure. (CR E1889)

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 5
 Cosponsors 4
All 4 Democratic 3 Independent 1
D
Velázquez, Nydia M.
New York · Mar 15, 1994
 D
Kaptur, Marcy
Ohio · Apr 29, 1993
 D
Pelosi, Nancy
California · Mar 8, 1993
 I
Sanders, Bernard
Vermont · Mar 2, 1993
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 916: Prescription Drug Prices Review Board Act of 1993. 103rd Congress. Open America. https://openamerica.io/bill/103-HR-916/
MLA
"H.R. 916: Prescription Drug Prices Review Board Act of 1993." 103rd Congress, 2026, Open America, https://openamerica.io/bill/103-HR-916/.
Bluebook (legal)
H.R. 916, 103rd Cong. (2026), https://openamerica.io/bill/103-HR-916/.
Markdown link
[H.R. 916: Prescription Drug Prices Review Board Act of 1993](https://openamerica.io/bill/103-HR-916/)
Report a problem